Taiwan - kinesisk - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

新喜國際企業股份有限公司 台南市鹽水區孫厝里孫厝寮４之６號 (72175181) - estrogen conjugated - 糖衣錠 - estrogen conjugated (6816000401) 1.25mg - conjugated estrogens - 卵巢機能不全、月經不順、月經困難、機能性子宮出血

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.3 mg - tablet, film coated - excipient ingredients: sucrose; hyprolose; macrogol 400; carnauba wax; hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; polysorbate 80; quinoline yellow aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1. premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 0.625 milligram - natural and semisynthetic estrogens, plain

Irland - engelsk - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 1.25 milligram - natural and semisynthetic estrogens, plain

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

sanval comÉrcio e indÚstria ltda - estrogÊnios conjugados, sulfato, sulfato de estrona - hormonios sexuais exclusive ocitocicos

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

aché laboratórios farmacêuticos s.a - estrogenos assocs a outros farmacos exclusive androgenos

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

prodotti laboratÓrio farmacÊutico ltda. - estrogenos assocs a outros farmacos exclusive androgenos

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

quimica haller ltda - estrogenos assocs a outros farmacos exclusive androgenos

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

monsanto do brasil ltda - estrogenos simples

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

revvity pty ltd - ct852 - estrogen (oestrogen) ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of estrogen (oestrogen) hormones in a clinical specimen.